KNSA Stock Analysis: Buy, Sell, or Hold?
KNSA - Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
$59.49
2.36 (4.13%)
▲
5d:
+13.66%
30d:
+10.89%
90d:
+29.21%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When KNSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: KNSA is 8.6% above its trading range ($54.78). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: KNSA is 8.6% above its trading range ($54.78). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$85.56
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$53.13
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KNSA is currently trading at $59.49, which is considered extended relative to its 30-day fair value range of $48.74 to $54.78. From a valuation perspective, the stock is trading at a premium (Forward PE: 33.9) compared to its historical average (27.2). At these levels, the market is pricing in 7.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, KNSA is in a strong uptrend. The price is approaching resistance at $59.36. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KNSA is in a strong uptrend. The price is approaching resistance at $59.36. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$48.74 -
$54.78
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
56.5%
Protect Your Profits
KNSA is technically overbought (RSI 73). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+8.6% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.1%)
- NEUTRAL: Near Wall St target ($63.50)
- NEUTRAL: PE elevated vs history but 7.6% growth expectation is conservative given 146% recent growth
Trading Range Analysis
30-Day Trading Range
$48.74 -
$54.78
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$3.83
(6.4%)
Support & Resistance Levels
Support Level
$48.49
Resistance Level
$59.36
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
33.85
Wall Street Target
$63.50
(+6.7%)
Revenue Growth (YoY)
55.5%
Earnings Growth (YoY)
145.5%
Profit Margin
9.7%
Valuation Premium vs History
+7.6% premium
PE vs Historical
33.9 vs 27.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.6%
(market-implied from PE analysis)
1-Year Target
$64.01
(+8%)
2-Year Target
$68.88
(+16%)
3-Year Target
$74.11
(+25%)
3-Yr Target (if PE normalizes)
(PE: 34→27)
PE COMPRESSION
$59.55
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 33.8, Growth: 46.5%)
$186.89
(+214%)
Base:
(SPY PE: 21.8, Growth: 46.5%)
$120.25
(+102%)
Bear:
(PE: 18.5, Growth: 46.5%)
$102.21
(+72%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (63x PE), but valuation improves significantly next year (34x PE) as earnings recover.
Trailing PE: 62.78 | Current EPS (TTM): $0.91
Bull Case
$121.37
(+104%)
Analyst growth 93.1%, PE expands to 69.1
Base Case
$110.34
(+86%)
Market implied 93.1%, PE stable at 62.8
Bear Case
$38.85
(-35%)
Severe decline -20.0%, PE contracts to 53.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 24, 2026 2:40 AM ET
Data refreshes hourly during market hours. Next update: 3:40 AM
Data refreshes hourly during market hours. Next update: 3:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KNSA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Ross Moat
SELL
1703 shares
2026-04-09
Michael R Megna
SELL
6625 shares
2026-04-09
Barry D Quart
SELL
6901 shares
2026-04-06
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
Advanced KNSA Option Strategies
Professional options setups generated by AI based on today's KNSA price and gamma walls.
